INVEX THERAPEUTICS LTD - Announcements

10.0%

11.0¢

Market Cap $8.266M

Healthcare Biotechnology

Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical... Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Our primary focus is on the orphan disease Idiopathic Intracranial Hypertension (IIH), a large and growing market opportunity with no regulatory cleared treatmentsMore

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IXC	Appendix 4E and Annual Report to shareholders	PRICE SENSITIVE	11/08/25	2.01MB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/07/25	412.29KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	08/04/25	391.39KB	Share
IXC	Appendix 4D and Half Year Report	PRICE SENSITIVE	07/02/25	526.67KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/01/25	453.94KB	Share
IXC	Invex Receives $0.22m R&D Tax Rebate from UK Government	PRICE SENSITIVE	20/01/25	183.57KB	Share
IXC	Improved Neuronal Cell Survival in 3D Model of Alzheimer's	PRICE SENSITIVE	16/12/24	277.69KB	Share
IXC	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	08/10/24	393.01KB	Share
IXC	Appendix 4E and Annual Report to shareholders	PRICE SENSITIVE	22/08/24	8.37MB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/07/24	396.95KB	Share
IXC	Invex receives R&D Tax Rebate	PRICE SENSITIVE	21/06/24	187.63KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	12/04/24	480.45KB	Share
IXC	ATO Class Ruling Return of Capital	PRICE SENSITIVE	20/03/24	349.06KB	Share
IXC	Appendix 4D and Half year report	PRICE SENSITIVE	16/02/24	544.81KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	11/01/24	460KB	Share
IXC	Invex and Peptron Mutually Terminate Manufacturing Agreement	PRICE SENSITIVE	22/12/23	180.45KB	Share
IXC	Invex Granted European Patent for Exenatide in Hydrocephalus	PRICE SENSITIVE	22/11/23	209.03KB	Share
IXC	Proposed Capital Return to Shareholders of $14.0 Million	PRICE SENSITIVE	01/11/23	189.67KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	12/10/23	440.19KB	Share
IXC	Invex issued US patent for Traumatic Brain Injury	PRICE SENSITIVE	23/08/23	207.93KB	Share
IXC	Invex to close IIH Evolve Phase III Clinical Trial	PRICE SENSITIVE	21/08/23	217.85KB	Share
IXC	Trading Halt	PRICE SENSITIVE	18/08/23	218.31KB	Share
IXC	Appendix 4E and Annual Report to shareholders	PRICE SENSITIVE	17/08/23	1.1MB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	10/07/23	432.64KB	Share
IXC	Phase III Clinical Trial Update and New IIH Market Analysis	PRICE SENSITIVE	28/06/23	297.29KB	Share
IXC	Invex Granted European Orphan Drug Designation for TBI	PRICE SENSITIVE	23/06/23	190.65KB	Share
IXC	Invex Receives Regulatory Approval for IIH EVOLVE in France	PRICE SENSITIVE	21/04/23	197.22KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/04/23	428.6KB	Share
IXC	Israel Ministry of Health Approval for IIH EVOLVE	PRICE SENSITIVE	20/04/23	195.97KB	Share
IXC	German Approval for IIH EVOLVE Phase 3 Clinical Trial	PRICE SENSITIVE	20/03/23	195.69KB	Share
IXC	Half Year Accounts	PRICE SENSITIVE	17/02/23	404.06KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/23	451.58KB	Share
IXC	First US Clinical Site Activated in IIH EVOLVE Phase III	PRICE SENSITIVE	19/01/23	198.37KB	Share
IXC	Invex Receives Approval for Paediatric Plan from the EMA	PRICE SENSITIVE	14/12/22	198.56KB	Share
IXC	MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ	PRICE SENSITIVE	25/11/22	193.89KB	Share
IXC	First Patient Randomised in IIH EVOLVE Phase III Trial	PRICE SENSITIVE	21/11/22	205.06KB	Share
IXC	Invex Receives $0.46 Million R&D Tax Rebate	PRICE SENSITIVE	01/11/22	191.88KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/22	436.09KB	Share
IXC	First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial	PRICE SENSITIVE	24/10/22	195.69KB	Share
IXC	First Australian Site Activated in IIH EVOLVE Phase 3	PRICE SENSITIVE	24/10/22	192.5KB	Share
IXC	Second HREC Approval for IIH EVOLVE Phase III Clinical Trial	PRICE SENSITIVE	30/09/22	206.16KB	Share
IXC	4E and Annual Report to shareholders	PRICE SENSITIVE	19/08/22	7.16MB	Share
IXC	Invex receives IND approval	PRICE SENSITIVE	19/08/22	212.82KB	Share
IXC	Trading Halt	PRICE SENSITIVE	18/08/22	212.3KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	06/07/22	454.29KB	Share
IXC	HREC and TGA Approval to Commence Phase 3 in Australia	PRICE SENSITIVE	04/07/22	207.47KB	Share
IXC	Invex Receives UK Approval to Commence Phase III Trial	PRICE SENSITIVE	29/06/22	201.44KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	19/04/22	480.95KB	Share
IXC	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/22	1.02MB	Share
IXC	New Executive Director and Chairman Agreements	PRICE SENSITIVE	31/01/22	200.14KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/22	484.39KB	Share
IXC	Appointment IIH EVOLVE Phase III Trial Steering Group Chair	PRICE SENSITIVE	17/12/21	190.05KB	Share
IXC	Global Phase 3 Trial of Presendin to Launch in Q4 2021	PRICE SENSITIVE	04/11/21	275.06KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/10/21	494.63KB	Share
IXC	Notice of Investor Call and Presentation	PRICE SENSITIVE	27/09/21	891.41KB	Share
IXC	Exclusive Collaboration and Manufacturing Agreement	PRICE SENSITIVE	27/09/21	201.53KB	Share
IXC	Trading Halt	PRICE SENSITIVE	24/09/21	541.45KB	Share
IXC	Appendix 4E and Annual Report	PRICE SENSITIVE	27/08/21	14.93MB	Share
IXC	Invex Granted Key European Patent for Exenatide	PRICE SENSITIVE	16/08/21	185.45KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/07/21	582.27KB	Share
IXC	Invex Receives Written Response from FDA on Type C Meeting	PRICE SENSITIVE	15/06/21	189.37KB	Share
IXC	Invex Granted Type C Meeting with FDA	PRICE SENSITIVE	22/04/21	183.16KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	13/04/21	506.84KB	Share
IXC	Half Yearly Report and Accounts	PRICE SENSITIVE	15/02/21	1.15MB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	11/01/21	507.99KB	Share
IXC	Invex Successfully Concludes Protocol Assistance with EMA	PRICE SENSITIVE	23/12/20	215KB	Share
IXC	Chairman's Address to Shareholders and Presentation	PRICE SENSITIVE	18/11/20	444.13KB	Share
IXC	Investor Presentation	PRICE SENSITIVE	05/11/20	1.05MB	Share
IXC	Invex Provides Development Update	PRICE SENSITIVE	30/10/20	245.28KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/20	434.95KB	Share
IXC	Appendix 4E and Annual Report	PRICE SENSITIVE	28/08/20	1.22MB	Share
IXC	Quarterly Report and Appendix 4C with appendix	PRICE SENSITIVE	07/08/20	491.53KB	Share
IXC	Quarterly Report and Appendix 4C	PRICE SENSITIVE	24/07/20	453KB	Share
IXC	Initial FDA and EMA Advice on Presendin Development	PRICE SENSITIVE	23/07/20	223.03KB	Share
IXC	Trading Halt	PRICE SENSITIVE	22/07/20	352.88KB	Share
IXC	Notice of Allowance for Key US Exenatide Patent	PRICE SENSITIVE	21/07/20	177.34KB	Share
IXC	Phase II Clinical Results and Capital Raising Presentation	PRICE SENSITIVE	22/05/20	1.01MB	Share
IXC	Succesful $26 million Share Placement	PRICE SENSITIVE	22/05/20	252.04KB	Share
IXC	Exenatide Meets Key Endpoints in IIH Clinical Trial	PRICE SENSITIVE	20/05/20	569.52KB	Share
IXC	Trading Halt	PRICE SENSITIVE	18/05/20	374.82KB	Share
IXC	Quarterly Report and Appendix 4C	PRICE SENSITIVE	02/04/20	382.7KB	Share
IXC	Appendix 4D and Half-year Report	PRICE SENSITIVE	27/02/20	397.41KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	17/01/20	321.22KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	17/10/19	285.38KB	Share
IXC	Phase II Recruitment Completed	PRICE SENSITIVE	15/10/19	148.82KB	Share
IXC	Japanese Patent Granted	PRICE SENSITIVE	07/10/19	145.83KB	Share
IXC	Preliminary Final Report	PRICE SENSITIVE	28/08/19	531.12KB	Share
IXC	Appendix 4C - quarterly	PRICE SENSITIVE	24/07/19	302.05KB	Share

IXC Appendix 4E and Annual Report to shareholders
11/08/25	PRICE SENSITIVE	2.01MB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
23/07/25	PRICE SENSITIVE	412.29KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
08/04/25	PRICE SENSITIVE	391.39KB	Share
IXC Appendix 4D and Half Year Report
07/02/25	PRICE SENSITIVE	526.67KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
22/01/25	PRICE SENSITIVE	453.94KB	Share
IXC Invex Receives $0.22m R&D Tax Rebate from UK Government
20/01/25	PRICE SENSITIVE	183.57KB	Share
IXC Improved Neuronal Cell Survival in 3D Model of Alzheimer's
16/12/24	PRICE SENSITIVE	277.69KB	Share
IXC Quarterly Activities Report and Appendix 4C
08/10/24	PRICE SENSITIVE	393.01KB	Share
IXC Appendix 4E and Annual Report to shareholders
22/08/24	PRICE SENSITIVE	8.37MB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
23/07/24	PRICE SENSITIVE	396.95KB	Share
IXC Invex receives R&D Tax Rebate
21/06/24	PRICE SENSITIVE	187.63KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
12/04/24	PRICE SENSITIVE	480.45KB	Share
IXC ATO Class Ruling Return of Capital
20/03/24	PRICE SENSITIVE	349.06KB	Share
IXC Appendix 4D and Half year report
16/02/24	PRICE SENSITIVE	544.81KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
11/01/24	PRICE SENSITIVE	460KB	Share
IXC Invex and Peptron Mutually Terminate Manufacturing Agreement
22/12/23	PRICE SENSITIVE	180.45KB	Share
IXC Invex Granted European Patent for Exenatide in Hydrocephalus
22/11/23	PRICE SENSITIVE	209.03KB	Share
IXC Proposed Capital Return to Shareholders of $14.0 Million
01/11/23	PRICE SENSITIVE	189.67KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
12/10/23	PRICE SENSITIVE	440.19KB	Share
IXC Invex issued US patent for Traumatic Brain Injury
23/08/23	PRICE SENSITIVE	207.93KB	Share
IXC Invex to close IIH Evolve Phase III Clinical Trial
21/08/23	PRICE SENSITIVE	217.85KB	Share
IXC Trading Halt
18/08/23	PRICE SENSITIVE	218.31KB	Share
IXC Appendix 4E and Annual Report to shareholders
17/08/23	PRICE SENSITIVE	1.1MB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
10/07/23	PRICE SENSITIVE	432.64KB	Share
IXC Phase III Clinical Trial Update and New IIH Market Analysis
28/06/23	PRICE SENSITIVE	297.29KB	Share
IXC Invex Granted European Orphan Drug Designation for TBI
23/06/23	PRICE SENSITIVE	190.65KB	Share
IXC Invex Receives Regulatory Approval for IIH EVOLVE in France
21/04/23	PRICE SENSITIVE	197.22KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
20/04/23	PRICE SENSITIVE	428.6KB	Share
IXC Israel Ministry of Health Approval for IIH EVOLVE
20/04/23	PRICE SENSITIVE	195.97KB	Share
IXC German Approval for IIH EVOLVE Phase 3 Clinical Trial
20/03/23	PRICE SENSITIVE	195.69KB	Share
IXC Half Year Accounts
17/02/23	PRICE SENSITIVE	404.06KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
25/01/23	PRICE SENSITIVE	451.58KB	Share
IXC First US Clinical Site Activated in IIH EVOLVE Phase III
19/01/23	PRICE SENSITIVE	198.37KB	Share
IXC Invex Receives Approval for Paediatric Plan from the EMA
14/12/22	PRICE SENSITIVE	198.56KB	Share
IXC MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
25/11/22	PRICE SENSITIVE	193.89KB	Share
IXC First Patient Randomised in IIH EVOLVE Phase III Trial
21/11/22	PRICE SENSITIVE	205.06KB	Share
IXC Invex Receives $0.46 Million R&D Tax Rebate
01/11/22	PRICE SENSITIVE	191.88KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
27/10/22	PRICE SENSITIVE	436.09KB	Share
IXC First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
24/10/22	PRICE SENSITIVE	195.69KB	Share
IXC First Australian Site Activated in IIH EVOLVE Phase 3
24/10/22	PRICE SENSITIVE	192.5KB	Share
IXC Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
30/09/22	PRICE SENSITIVE	206.16KB	Share
IXC 4E and Annual Report to shareholders
19/08/22	PRICE SENSITIVE	7.16MB	Share
IXC Invex receives IND approval
19/08/22	PRICE SENSITIVE	212.82KB	Share
IXC Trading Halt
18/08/22	PRICE SENSITIVE	212.3KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
06/07/22	PRICE SENSITIVE	454.29KB	Share
IXC HREC and TGA Approval to Commence Phase 3 in Australia
04/07/22	PRICE SENSITIVE	207.47KB	Share
IXC Invex Receives UK Approval to Commence Phase III Trial
29/06/22	PRICE SENSITIVE	201.44KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
19/04/22	PRICE SENSITIVE	480.95KB	Share
IXC Half Yearly Report and Accounts
22/02/22	PRICE SENSITIVE	1.02MB	Share
IXC New Executive Director and Chairman Agreements
31/01/22	PRICE SENSITIVE	200.14KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
24/01/22	PRICE SENSITIVE	484.39KB	Share
IXC Appointment IIH EVOLVE Phase III Trial Steering Group Chair
17/12/21	PRICE SENSITIVE	190.05KB	Share
IXC Global Phase 3 Trial of Presendin to Launch in Q4 2021
04/11/21	PRICE SENSITIVE	275.06KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
20/10/21	PRICE SENSITIVE	494.63KB	Share
IXC Notice of Investor Call and Presentation
27/09/21	PRICE SENSITIVE	891.41KB	Share
IXC Exclusive Collaboration and Manufacturing Agreement
27/09/21	PRICE SENSITIVE	201.53KB	Share
IXC Trading Halt
24/09/21	PRICE SENSITIVE	541.45KB	Share
IXC Appendix 4E and Annual Report
27/08/21	PRICE SENSITIVE	14.93MB	Share
IXC Invex Granted Key European Patent for Exenatide
16/08/21	PRICE SENSITIVE	185.45KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
23/07/21	PRICE SENSITIVE	582.27KB	Share
IXC Invex Receives Written Response from FDA on Type C Meeting
15/06/21	PRICE SENSITIVE	189.37KB	Share
IXC Invex Granted Type C Meeting with FDA
22/04/21	PRICE SENSITIVE	183.16KB	Share
IXC Appendix 4C - quarterly
13/04/21	PRICE SENSITIVE	506.84KB	Share
IXC Half Yearly Report and Accounts
15/02/21	PRICE SENSITIVE	1.15MB	Share
IXC Appendix 4C - quarterly
11/01/21	PRICE SENSITIVE	507.99KB	Share
IXC Invex Successfully Concludes Protocol Assistance with EMA
23/12/20	PRICE SENSITIVE	215KB	Share
IXC Chairman's Address to Shareholders and Presentation
18/11/20	PRICE SENSITIVE	444.13KB	Share
IXC Investor Presentation
05/11/20	PRICE SENSITIVE	1.05MB	Share
IXC Invex Provides Development Update
30/10/20	PRICE SENSITIVE	245.28KB	Share
IXC Appendix 4C - quarterly
23/10/20	PRICE SENSITIVE	434.95KB	Share
IXC Appendix 4E and Annual Report
28/08/20	PRICE SENSITIVE	1.22MB	Share
IXC Quarterly Report and Appendix 4C with appendix
07/08/20	PRICE SENSITIVE	491.53KB	Share
IXC Quarterly Report and Appendix 4C
24/07/20	PRICE SENSITIVE	453KB	Share
IXC Initial FDA and EMA Advice on Presendin Development
23/07/20	PRICE SENSITIVE	223.03KB	Share
IXC Trading Halt
22/07/20	PRICE SENSITIVE	352.88KB	Share
IXC Notice of Allowance for Key US Exenatide Patent
21/07/20	PRICE SENSITIVE	177.34KB	Share
IXC Phase II Clinical Results and Capital Raising Presentation
22/05/20	PRICE SENSITIVE	1.01MB	Share
IXC Succesful $26 million Share Placement
22/05/20	PRICE SENSITIVE	252.04KB	Share
IXC Exenatide Meets Key Endpoints in IIH Clinical Trial
20/05/20	PRICE SENSITIVE	569.52KB	Share
IXC Trading Halt
18/05/20	PRICE SENSITIVE	374.82KB	Share
IXC Quarterly Report and Appendix 4C
02/04/20	PRICE SENSITIVE	382.7KB	Share
IXC Appendix 4D and Half-year Report
27/02/20	PRICE SENSITIVE	397.41KB	Share
IXC Appendix 4C - quarterly
17/01/20	PRICE SENSITIVE	321.22KB	Share
IXC Appendix 4C - quarterly
17/10/19	PRICE SENSITIVE	285.38KB	Share
IXC Phase II Recruitment Completed
15/10/19	PRICE SENSITIVE	148.82KB	Share
IXC Japanese Patent Granted
07/10/19	PRICE SENSITIVE	145.83KB	Share
IXC Preliminary Final Report
28/08/19	PRICE SENSITIVE	531.12KB	Share
IXC Appendix 4C - quarterly
24/07/19	PRICE SENSITIVE	302.05KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 11.0¢		Change 0.010(10.0%)		Mkt cap ! $8.266M

Open	High	Low	Value	Volume
11.0¢	11.0¢	11.0¢	$2.306K	20.96K

Buyers (Bids)

No.	Vol.	Price($)
2	51528	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	4039	1

View Market Depth

No.	Vol.	Price($)
2	51528	0.095
1	100000	0.091
1	50000	0.087
1	50000	0.085
1	38671	0.075

Price($)	Vol.	No.
0.110	4039	1
0.145	2000	1
0.150	713	1
0.000	0	0
0.000	0	0

Last trade - 16.10pm 16/09/2025 (20 minute delay)

IXC (ASX) Chart

INVEX THERAPEUTICS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories